SCHEMBL4388095

SCHEMBL4388095

Cc1nc(-c2ccnc(Nc3cccc(O)c3)n2)sc1C

nearest known ligand 0.68

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 14/20 0.68
CDK4 P11802 10/20 0.68
SYK P43405 6/20 0.56
SRC P12931 3/20 0.56
ZAP70 P43403 3/20 0.56
PLK1 P53350 4/20 0.55
KDR P35968 1/20 0.55
PTK2 Q05397 1/20 0.55
AURKB Q96GD4 1/20 0.55
CCNA2 P20248 3/20 0.54
CCNT1 O60563 2/20 0.54
CDK1 P06493 2/20 0.54
CCNB1 P14635 2/20 0.54
CDK7 P50613 2/20 0.54
CDK9 P50750 2/20 0.54
CCNH P51946 2/20 0.54
CCNA1 P78396 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4391357 0.86 CDK2 (0.68) CDK2CDK4SYKSRCZAP70
SCHEMBL4383709 0.85 CDK2 (0.65) CDK2CDK4SYKSRCZAP70
SCHEMBL14378999 0.85 CDK2 (0.64) CDK2CDK4SYKSRCZAP70
SCHEMBL14008738 0.84 CDK2 (0.51) CDK2CDK4SYKSRCZAP70
SCHEMBL4385809 0.83 AURKA (0.58) CDK2CDK4SYKSRCZAP70
SCHEMBL4386032 0.82 CDK2 (0.72) CDK2CDK4SYKSRCZAP70
SCHEMBL14216016 0.81 ZAP70 (0.72) CDK2CDK4SYKSRCZAP70
SCHEMBL14216178 0.81 SYK (0.70) CDK2CDK4SYKSRCZAP70
SCHEMBL29644961 0.81 CDK2 (1.00) CDK2CDK4PLK1AURKBCDK1
SCHEMBL2285895 0.81 CDK2 (1.00) CDK2CDK4PLK1AURKBCDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1751146-B1 PYRIDINYL- OR PYRIMIDINYL THIAZOLES WITH PROTEIN KINASE INHIBITING ACTIVITY CYCLACEL LTD (GB) 2009-12-02 EP claimed
US-20080318954-A1 Compounds CYCLACEL LIMITED (GB) 2008-12-25 US claimed
CN-1914199-A Pyridyl or pyrimidyl thiazole compounds having protein kinase inhibitory activity CYCLACEL LTD (GB) 2007-02-14 CN claimed
EP-1751146-B1 PYRIDINYL- OR PYRIMIDINYL THIAZOLES WITH PROTEIN KINASE INHIBITING ACTIVITY CYCLACEL LTD (GB) 2009-12-02 EP disclosed
EP-1751146-B1 PYRIDINYL- OR PYRIMIDINYL THIAZOLES WITH PROTEIN KINASE INHIBITING ACTIVITY CYCLACEL LTD (GB) 2009-12-02 EP disclosed
US-20080318954-A1 Compounds CYCLACEL LIMITED (GB) 2008-12-25 US disclosed
US-20080318954-A1 Compounds CYCLACEL LIMITED (GB) 2008-12-25 US disclosed
US-20080318954-A1 Compounds CYCLACEL LIMITED (GB) 2008-12-25 US disclosed
CN-1914199-A Pyridyl or pyrimidyl thiazole compounds having protein kinase inhibitory activity CYCLACEL LTD (GB) 2007-02-14 CN disclosed
WO-2005075468-A2 PYRIDINYL - OR PYRIMIDINYL THIAZOLES WITH PROTEIN KINASE INHIBITING ACTIVITY CYCLACEL LIMITED (GB) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318954-A1 Compounds CBR3, NR3C2, NR5A1 CDK2 1186/4885CDK4 607/4885SYK 3919/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.